Campus alert status is orange: For the latest campus alert status, news and resources, visit umassmed.edu/coronavirus.

Search Close Search
Search Close Search
Page Menu

The NeuroNexus Institute at UMass Medical School

Nexus: a connection, hub or junction, a connected group or series, the center or focus.

  • The NeuroNexus Institute at UMass Medical School brings together basic scientists, clinicians and trainees with the goal of understanding nervous system function and dysfunction, leading to improved diagnosis and treatment of neurological, neurodevelopmental and psychiatric disorders.
  • Institute faculty also teach, supervise and mentor the next generation of academic and industry leaders, medical practitioners and educators. 
  • Our community also reaches out to increase public awareness of nervous system function and diseases, of fact-based scientific investigation, and to reduce the stigma of neurological and psychiatric disorders.
  • Please explore these pages to learn more about our people, projects and progress.

Our Mission: From Discoveries to Therapies

The mission of the NeuroNexus Institute at UMass Medical School is to catalyze interactions between basic scientists and translational or clinician scientists, forming interdisciplinary teams that tackle innovative projects, achieve breakthroughs in basic neuroscience knowledge, and accelerate development and implementation of innovative therapies to treat neurological conditions.

Our Vision

To integrate our extensive local community of basic and clinical neuroscientists into a hub of interactions, leading to innovation, discovery and development of new treatments for neurological disorders, and attract diverse funding sources.

Our Approach

  • Understand principles of nervous system physiology
  • Leverage these principles of neuroscience to understand disease mechanisms
  • Accelerate treatments
  • Educate future generations of academic leaders and medical practitioners
  • Impact patient care
  • Reach out and Educate the public of the Commonwealth of Massachusetts and beyond

 

News

Getting Results…
  • UMass Chan clinical trial shows antisense oligonucleotide safely suppresses mutant ALS gene in pilot human study
    Research News

    UMass Chan clinical trial shows antisense oligonucleotide safely suppresses mutant ALS gene in pilot human study

    Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of an ALS gene in a single-patient pilot study.

    Read more
  • Sio Gene Therapies reports positive interim data for gene therapy trial
    Research News

    Sio Gene Therapies reports positive interim data for gene therapy trial

    Sio Gene Therapies, a clinical-stage company focused on developing gene therapies for neurodegenerative diseases, presented positive interim data from its Phase I/II study of AXO-AAV-GM1, an adeno-associated viral vector-based gene therapy candidate for GM1 gangliosidosis that was licensed from UMass Chan.

    Read more
  • Riaan Research Initiative funds Cockayne syndrome gene replacement therapy research at UMass Chan Medical School
    Research News

    Riaan Research Initiative funds Cockayne syndrome gene replacement therapy research at UMass Chan Medical School

    Riaan Research Initiative, a non-profit organization, and UMass Chan Medical School are entering into an agreement to fund, research and develop a gene replacement therapy to combat Cockayne syndrome, a fatal autosomal recessive disorder.

    Read more
  • Two new studies from Daryl Bosco lab shed new light on ALS mechanisms
    Research News

    Two new studies from Daryl Bosco lab shed new light on ALS mechanisms

    Two studies from the lab of Daryl Bosco, PhD, offer new insights into the biochemical and molecular mechanisms that cause amyotrophic lateral sclerosis.

    Read more